Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment of a cancer genomic profile test for patients with metastatic breast cancer.
Fukada I, Mori S, Hayashi N, Hosonaga M, Yamazaki M, Wang X, Kawai S, Inagaki L, Ozaki Y, Kobayashi K, Hara F, Kobayashi T, Ueki A, Osako T, Tonooka A, Takeuchi K, Ueno T, Takano T, Ohno S, Takahashi S. Fukada I, et al. Among authors: hara f. Sci Rep. 2022 Mar 21;12(1):4813. doi: 10.1038/s41598-022-08925-3. Sci Rep. 2022. PMID: 35315838 Free PMC article.
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y; SELECT BC Study Group. Takashima T, et al. Among authors: hara f. Lancet Oncol. 2016 Jan;17(1):90-8. doi: 10.1016/S1470-2045(15)00411-8. Epub 2015 Nov 27. Lancet Oncol. 2016. PMID: 26617202 Clinical Trial.
A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.
Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, Masuda N, Morita S, Toi M, Ohno S. Yamamoto Y, et al. Among authors: hara f. Jpn J Clin Oncol. 2018 Sep 1;48(9):855-859. doi: 10.1093/jjco/hyy097. Jpn J Clin Oncol. 2018. PMID: 30020510 Clinical Trial.
Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients.
Masuda N, Inoue K, Nakamura R, Rai Y, Mukai H, Ohno S, Hara F, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Huang X, Iwata H. Masuda N, et al. Among authors: hara f. Int J Clin Oncol. 2019 Mar;24(3):262-273. doi: 10.1007/s10147-018-1359-3. Epub 2018 Nov 3. Int J Clin Oncol. 2019. PMID: 30392115 Free PMC article. Clinical Trial.
Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
Taira N, Kashiwabara K, Tsurutani J, Kitada M, Takahashi M, Kato H, Kikawa Y, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T, Takashima T, Aihara T, Mukai H, Hara F. Taira N, et al. Among authors: hara f. Breast Cancer. 2022 Jan;29(1):131-143. doi: 10.1007/s12282-021-01290-5. Epub 2021 Sep 7. Breast Cancer. 2022. PMID: 34491513 Free PMC article. Clinical Trial.
Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.
Ozaki Y, Aoyama Y, Masuda J, Inagaki L, Kawai S, Shibayama T, Maeda T, Kurata M, Yoshida K, Saeki S, Hosonaga M, Fukada I, Hara F, Kobayashi T, Kobayashi K, Miyake S, Takano T, Ueno T, Ohno S. Ozaki Y, et al. Among authors: hara f. BMC Cancer. 2022 Jan 4;22(1):36. doi: 10.1186/s12885-021-09128-1. BMC Cancer. 2022. PMID: 34983437 Free PMC article.
194 results